The Motley Fool

3 quality FTSE 250 stocks I’d snap up right now

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businessman using calculator next to laptop
Image source: Getty Images.

I’m always on the hunt for stocks backed by good-quality businesses and with the potential to go places. Here are three I’m keen on right now from the FTSE 250 index.

Food ingredients and additives

Tate & Lyle (LSE: TATE), the food ingredients and additives manufacturer and supplier, delivered decent adjusted half-year results at the beginning of November. Sales, earnings and the interim dividend all rose by small, single-digit percentages.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Chief executive Nick Hampton said in the report that in the firm’s Food & Beverage Solutions division, an increased focus on pricing and mix management delivered “strong” growth.  Meanwhile, the profit from the Primary Products division came in lower because of “challenging” market conditions. But both divisions achieved productivity gains and good discipline on costs led to higher cash generation.

The company is on a drive to simplify its business, which is “driving momentum across the organisation and supporting performance.” However, the directors expect a flat outcome with earnings for the full year.

Meanwhile, with the share price close to 734p, the forward-looking earnings multiple for the trading year to March 2021 is just under 13 and the anticipated dividend yield is 4.25%. I think that looks like decent value.

Precision engineering

IMI (LSE: IMI) designs, manufactures and services “highly engineered” products that control the precise movement of fluids, such as actuators and valves.

In the third-quarter update released in November, the company said it is making “good” progress with its business-improvement and cost-reduction initiatives, and in the face of weak markets, has been working hard to reduce costs and improve margins. Sales came in a little lower in the quarter, but margins were up.

Looking ahead, the directors think that revenue in the entire second half of the year will show another small decline when compared to the 2018 equivalent period. But profits should come in flat. Meanwhile, the firm has finished its structural review and has a plan to drive the business forward in the coming years.

With the share price close to 1,135p, the forward-looking earnings multiple for 2020 is just over 15 and the anticipated dividend yield is around 3.8%. I think the stock is attractive.


Mediclinic International (LSE: MDC) delivers private healthcare in Southern Africa, Switzerland and the Middle East. The half-year results report released in mid-November showed revenue up 9% compared to the equivalent period the year before and flat earnings.

Chief executive Dr Ronnie van der Merwe said in the report that all three divisions grew revenue, EBITDA and patient volumes in the period. And the firm is making progress adapting the business to current healthcare trends and changing regulatory environments, “especially at Hirslanden in Switzerland.

The company has a growth agenda and aims to expand by offering more services in the healthcare field such as day clinics, primary care facilities, sub-acute hospitals, radiology, precision medicine, IVF and digital healthcare solutions.   

Meanwhile, with the share price near 399p, the forward-looking earnings multiple for the trading year to March 2021 is just under 14 and the anticipated dividend yield is 2.1%, with the payment set to be covered a generous 3.5 times by predicted earnings. I’m tempted to buy some of the shares.

Overall, I reckon all three of these businesses are improving and the valuations remain modest.  

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended IMI. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.